Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

297.43 -1.03 (-0.35%)

Streaming Delayed Price Updated: 3:20 PM EST, Jan 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	363,793
Open	300.32
Bid (Size)	296.91 (100)
Ask (Size)	298.00 (200)
Prev. Close	298.46
Today's Range	294.29 - 305.68
52wk Range	26.70 - 317.72
Shares Outstanding	44,712,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

January 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

January 12, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Performance

YTD	+3.9%	+3.9%
1 Month	+7.6%	+7.6%
3 Month	+418.6%	+418.6%
6 Month	+454.6%	+454.6%
1 Year	+351.7%	+351.7%

More News

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

January 08, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Why Praxis Precision Medicines Stock Popped Today ↗

December 29, 2025

Via The Motley Fool

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗

December 29, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

Via Chartmill

Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗

December 29, 2025

Via Stocktwits

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

December 29, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

December 11, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

December 09, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

December 08, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 05, 2025

Via Chartmill

Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗

December 05, 2025

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

December 05, 2025

Via Chartmill

What's going on in today's pre-market session ↗

December 05, 2025

Via Chartmill

Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗

December 05, 2025

Via Stocktwits

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On? ↗

December 05, 2025

Via Benzinga

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗

December 05, 2025

Via Stocktwits

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

December 04, 2025

Via Chartmill

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

December 04, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

December 04, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?

Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.

What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?

Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?

The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market

What is the current price of Praxis Precision Medicines, Inc. - Common Stock?

The current price of Praxis Precision Medicines, Inc. - Common Stock is 297.43

When was Praxis Precision Medicines, Inc. - Common Stock last traded?

The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 01/15/26 03:20 PM ET

What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?

The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 13.30B

How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?

Praxis Precision Medicines, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.